why isn t my glp 1 working How Do You Know When Semaglutide GLP-1 Is Working? Can you Lose Weight Without

Originally developed for diabetes treatment, Ozempic (semaglutide) and its higher-dose counterpart Wegovy have shown remarkable efficacy in weight reduction, offering new hope for those struggling with weight issues

Waiting 4 weeks between dose escalations allows the body to adapt to increasing drug exposure and minimizes gastrointestinal adverse effects, the most common reason for treatment discontinuation

WHAT KAISER REQUIRES FIRST Step Therapy Requirements Even in regions where Kaiser covers Zepbound, you must typically "fail" multiple other treatments first: Kaiser Northwest Example (Most Documented) To qualify for Zepbound coverage in Kaiser Northwest, you must demonstrate: [3] Kaiser Zepbound Coverage Criteria BMI 30 (obesity) OR BMI 27 with a comorbidity (hypertension, diabetes, high cholesterol) Age 18+ Following a structured diet and exercise program (documented, not just attested) Failed at least 2 prior weight loss medications : Phentermine Diethylpropion Qsymia (phentermine/topiramate) Contrave (naltrexone/bupropion) Tried semaglutide (Wegovy or Ozempic) for minimum 6 months and either: It was ineffective (didn't achieve target weight loss) Cannot tolerate due to allergy, serious side effects, or contraindication Continuation Requirements (To Keep Coverage) Initial approval typically for 12 months Must document at least 5% weight loss after starting tirzepatide to continue coverage Bariatric medicine chart review required before switching from semaglutide to Zepbound Kaiser's Internal "Medical Weight Management" Program Kaiser often requires patients to enroll in their internal weight management program before approving GLP-1s

We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists

Initial management involves lifestyle and dietary modifications

The integration of these insights into clinical practice is expected to improve long-term outcomes and patient satisfaction in diabetes and obesity management